The purpose of this study is to develop and validate an Artificial intelligence (AI)-based tissue sample analysis tool that can predict response & progression rates to chemotherapy in intermediate-risk (IR) and high-risk (HR) Non-muscle invasive bladder cancer (NMIBC) patients. This study will use AI-based tissue sample analysis as a possible tool to help predict which patients are at high-risk for cancer recurrence and progression after surgery and chemotherapy treatment. Specimens will be obtained for each patient before treatment and at the 12, 24, & 36 month follow-up to be analyzed using the AI-based tool.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Marc Bjurlin
LCCC - Clinical Trials
Clinical or Medical
Observational
Cancer (Bladder)
24-1597
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
